On July 4, 2021, China’s National Medical Products Administration (NMPA), in conjunction with the China National Intellectual Property Administration (CNIPA), issued the Measures for the Implementation of Early Resolution Mechanisms for Drug Patent Disputes (Trial). The notification announces the launch of a patent information registration platform for NMPA-approved drugs, where drug patent holders should register and disclose drug their patent information as required. Any change of information should be updated timely. The patent information publicized on the platform will serve as the basis for the patent declaration made by the applicant for the listing registration of generic chemical drugs, Chinese medicines with the same name and the same prescription, and biosimilars.